Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C

doi:10.3748/wjg.v20.i30.10449

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 30

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6157)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-8) series.

Item

Count

PDF

410

WORD

184

HTML

2970

Tables (1-8)

205

Sum=3769

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1348

Download

1040

Sum=2388

Aug 14, 2014 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Research Report

World J Gastroenterol. Aug 14, 2014; 20(30): 10449-10456
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10449

Table 1 Characteristics of the study population

	HCV			Healthy subjects			Pvalue
	Median	LQ-UQ	Min-Max	Median	LQ-UQ	Min-Max	Pvalue
Age	32	23-48	18-61	32	23-48	26-56	P > 0.05
BMI	23.6	23.2-24.7	20.1-24.9	23.3	22.4-24.7	19.5-24.9	P > 0.05
ALT U/L	52	43-79	23-339
HCV viremia (IU/mL)	1230000	382000-3880000	112000-8950000
SOCS-3	5.17	2.09-9.78	0.5-24.53
HOMA	2.24	1.50-3.36	0.78-9.67	0.56	0.34-1.02	0.25-2	P = 0.0003
Visfatin (ng/mL)	2.64	1.17-3.58	0.45-9.37	2.75	2.47-3.8	1.26-5.27	P > 0.05
Omentin (ng/mL)	385.07	340.33-522.77	115.7-757.34	375.55	278.02-477.33	115.68-587.51	P > 0.05
Adiponectin (µg/mL)	7.23	5.48-8.72	3.51-18.48	9.335	6.275-11.20	5.89-15.33	P > 0.05
Resistin (ng/mL)	1.54	1.11-1.74	0.73-2.92	1.48	1.31-1.71	1.04-2.7	P > 0.05
Leptin (ng/mL)	4.85	2.425-13.6	0.77-54.65	5.785	3.81-17.06	1.85-42.76	P > 0.05
Osteopontin (ng/mL)	28.71	18.06-36.19	5.33-59.15	20.56	15.47-21.2	6.14-32.42	P > 0.05
	Number of patients (n)			Number of patients (n)
Age > 40	9			4			P > 0.05
Age < 40	22			5			P > 0.05
Women	10			4			P > 0.05
Men	21			5			P > 0.05

The mean HOMA-IR index in HCV infected patients was significantly higher compared to healthy controls (2.24 vs 0.59, P = 0.0003) (Table 1). However, there was no significant difference in adipocytokine concentration between patients with chronic hepatitis C and healthy subjects. LQ: Lower quartile; UQ: Upper quartile; BMI: Body mass index; ALT: Alanine aminotransferase; HCV: Hepatitis C virus; SOCS-3: Suppressor of cytokine signaling 3; HOMA: Homeostasis model assessment.

Table 2 Adipokines and homeostasis model assessment of insulin resistance in chronic hepatitis C

	Median (LQ-UQ)		Pvalue
	HOMA-IR > 2.5 (n= 15)	HOMA-IR < 2.5 (n= 16)
Omentin (ng/mL)	381.24 (332.79- 483.33)	399.91 (367.16-541.72)	Pvalue	P > 0.05
Adiponectin (μg/mL)	6.24 (5.48-7.92)	8.37 (5.63-12.18)	P > 0.05
Resistin (ng/mL)	1.56 (1.42-1.74)	1.24 (1.03-1.56)	P > 0.05
Leptin (ng/mL)	6.79 (2.34-13.11)	3.04 (2.51-17.2)	P > 0.05
Visfatin (ng/mL)	2.66 (1.09-3.12)	2.05 (1.17-3.3)	P > 0.05
Osteopontin (ng/mL)	28.71 (15.52-37.1)	31.18 (20.29-36.07)	P > 0.05

Adipokine levels were not related to HOMA-IR index in patients with chronic hepatitis C. HOMA-IR: Homeostasis model assessment of insulin resistance; LQ: Lower quartile; UQ: Upper quartile.

Table 3 Adipokines and liver steatosis in chronic hepatitis C

	With steatosis (n= 10)		Without steatosis (n= 21)		Pvalue
	Median (LQ-UQ)	Min-max	Median (LQ-UQ)	Min-max
SOCS3	6.553 (3.393-11.777)	1.042-24.537	5.106 (2.095-8.713)	0.5-17.95	P > 0.05
HOMA	2.815 (1.99-4.84)	1.25-9.67	1.995 (1.21-2.51)	0.78-7.25	P = 0.05
Adiponectin (μg/mL)	5.985 (4.83-7.23)	3.55-8.43	8.37 (5.71-9.07)	3.51-18.48	P = 0.047
Osteopontin (ng/mL)	33.51 (15.52-49.12)	5.33-59.15	24.7 (18.26-34.58)	11.57-47.85	P > 0.05
Leptin (ng/mL)	5.705 (3.04-17.2)	2.34-54.65	3.825 (1.33-13.11)	0.77-39.04	P > 0.05
Resistin (ng/mL)	1.65 (1.42-1.84)	1.17-2.36	1.51 (1.03-1.58)	0.73-2.92	P > 0.05
Omentin (ng/mL)	374.875 (332.79-483.33)	227.99-757.34	393.92 (360.09-522.77)	115.7-735.84	P > 0.05
Visfatin (ng/mL)	2.465 (1.37-3.12)	0.45-3.97	2.64 (1.17-4.08)	0.53-9.37	P > 0.05

Hepatic steatosis was related to increased HOMA-IR index (2.81 vs 1.99, P = 0.05) and reduced adiponectin level (5.96 vs 8.37, P = 0.04). SOCS-3: Suppressor of cytokine signaling 3; HOMA-IR: Homeostasis model assessment of insulin resistance; LQ: Lower quartile; UQ: Upper quartile.

Table 4 Adipokines and liver inflammation in chronic hepatitis C

	G≥2 (n= 9)		G < 2 (n= 22)		Pvalue
	Median (LQ-UQ)	Min-max	Median (LQ-UQ)	Min-max
Omentin (ng/mL)	381.24 (367.16-522.77)	115.7-757.34	389.46 (340.33-483.33)	227.99-735.84	P > 0.05
Adiponectin (μg/mL)	6.21 (5.71-7.56)	4.6-9.07	8 (5.48-9.06)	3.51-18.24	P > 0.05
Resistin (ng/mL)	1.24 (1.17-1.65)	0.91-2.36	1.55 (1.11-1.82)	0.73-2.92	P > 0.05
HOMA	2.1(1.59-3.99)	0.78-9.67	2.38 (1.25-2.84)	0.88-7.25	P > 0.05
Leptin (ng/mL)	10.83 (4.26-31.44)	1.69-54.65	3.43 (1.83-9.36)	0.77-39.04	P > 0.05
Visfatin (ng/mL)	2.05 (1.83-2.66)	0.65-8.89	2.78 (1.17-4.08)	0.45-9.37	P > 0.05
Osteopontin (ng/mL)	34.04 (32.7-36.19)	22.47-49.12	23.25 (15.05-36.07)	5.33-59.15	P = 0.03
SOCS-3	3.69 (2.67-7.05)	0.66-11.52	8.13 (1.74-11.78)	0.5-24.53	P > 0.05

Inflammatory activity (G ≥ 2) was associated with increased osteopontin concentration (34.04 vs 23.35, P = 0.03). No relationships were found between other adipokine concentrations and the grade of inflammatory activity. n: Number of patients, in liver biopsy: G: Grade of inflammation and necrosis; HOMA-IR: Homeostasis model assessment of insulin resistance; LQ: Lower quartile; UQ: Upper quartile.

Table 5 Adipokines and liver fibrosis in chronic hepatitis C

	S≥2 (n= 22)		S < 2 (n= 9)		Pvalue
	Median (LQ-UQ)	Min-max	Median (LQ-UQ)	Min-max
Omentin (ng/mL)	436.94 (367.16-538.15)	115.7-757.34	360.09 (296.34-383.55)	257.55-396.92	P = 0.03
Adiponectin (μg/mL)	7.39 (5.71-9.06)	4.6-18.48	6.46 (4.52-8.37)	3.51-11.28	P > 0.05
Resistin (ng/mL)	1.4 (1.03-1.58)	0.73-2.36	1.74 (1.54-2.67)	0.76-2.92	P = 0.047
HOMA (mmol/L)	2.1 (1.33-3.36)	0.78-9.77	2.5 (1.5-2.79)	0.88-5.17	P > 0.05
Leptin (ng/mL)	4.09 (2.51-8.56)	1.00-54.65	11.94 (1.17-21.5)	0.77-39.04	P > 0.05
Visfatin (ng/mL)	2.25 (1.17-3.3)	0.53-8.89	3.12 (1.57-5.26)	0.45-9.37	P > 0.05
Osteopontin (ng/mL)	32.84 (22.47-37.1)	8.46-59.15	20.29 (15.05-24.33)	5.33-38.46	P = 0.03
SOCS-3	4.51 (1.92-9.24)	0.66-24.53	8.61 (4.40-11.777)	0.5-17.95	P > 0.05

Advanced liver fibrosis (S ≥ 2) was more commonly observed in patients with increased serum levels of omentin and osteopontin (436.94 vs 360.09, P = 0.03 and 32.84 vs 20.29, P = 0.03) and reduced resistin concentration (1.40 vs 1.74, P = 0.047). Other adipokines were not related to the progression of liver fibrosis. No difference was found in HOMA-IR index according to stages of fibrosis in liver biopsy specimens. n: Number of patients; S: Stage of fibrosis; SOCS-3: Suppressor of cytokine signaling 3; HOMA-IR: Homeostasis model assessment of insulin resistance; LQ: Lower quartile; UQ: Upper quartile.

Table 6 Correlations between adipokines and hepatic expression of suppressor of cytokine signaling 3 in chronic hepatitis C

	SOCS-3	Pvalue
	Spearman’s rank correlationρ	Pvalue
Age	0.12	P > 0.05
HCV viral load (IU/mL)	0.15	P > 0.05
ALT (U/L)	0.41	P > 0.05
HOMA	0.39	P > 0.05
Adiponectin (μg/mL)	0.24	P > 0.05
Osteopontin (ng/mL)	0.30	P > 0.05
Visfatin (ng/mL)	0.23	P > 0.05
Resistin (ng/mL)	0.55	P > 0.05
Leptin (ng/mL)	0.14	P > 0.05
Omentin (ng/mL)	0.50	P > 0.05

No correlation was found between serum adipokine levels or HOMA-IR index and hepatic expression of SOCS-3. SOCS-3: Suppressor of cytokine signaling 3; HOMA-IR: Homeostasis model assessment of insulin resistance; ALT: Alanine aminotransferase.

Table 7 Adipokines and hepatitis C virus viremia

	VL≥600000 IU/mL (n= 12)		VL < 600000 IU/mL (n= 19)		Pvalue
	Median (LQ-UQ)	Min-max	Median (LQ-UQ)	Min-max
Age	32 (23-54)	18-61	32.5 (23.5-38)	18-61	P > 0.05
Adiponectin (μg/mL)	6.46 (5.48-8.72)	3.51-18.48	7.42 (5.48-8.75)	3.55-17.93	P > 0.05
Osteopontin (ng/mL)	31.18 (15.52-37.1)	11.57-59.15	26.84 (21.19-33.78)	5.33-54.98	P > 0.05
Leptin (ng/mL)	4.09 (1.59-21.5)	0.77-54.65	5.47 (2.51-13.11)	1.17-17.2	P > 0.05
Resistin (ng/mL)	1.42 (1.03-1.74)	0.73-2.92	1.56 (1.29-1.78)	0.87-2.71	P > 0.05
Omentin (ng/mL)	393.92 (342.46-534.21)	115.7-757.34	381.88 (312.96-497.43)	227.99-735.84	P > 0.05
HOMA	2.01 (1.5-3.99)	0.88-9.67	2.5 (1.25-3.36)	0.78-5.66	P > 0.05
Visfatin (ng/mL)	2.67 (1.17-3.97)	0.53-9.37	2.14 (1.23-3.11)	0.45-9.33	P > 0.05

Serum adipokine concentrations and HOMA-IR index were not found to be related to HCV viremia. VL: Viral load; SOCS-3: Suppressor of cytokine signaling 3: HOMA-IR: Homeostasis model assessment of insulin resistance; HCV: Hepatitis C virus; LQ: Lower quartile; UQ: Upper quartile.

Table 8 Adipokines and single nucleotide polymorphisms of interleukin 28B in chronic hepatitis C

	CC (n= 6)		TT/CT (n= 25)		Pvalue
	Median (LQ-UQ)	Min-max	Median (LQ-UQ)	Min-max
SOCS-3	11.52 (3.164-15.738)	2.17-17.95	5.10 (1.75-8.713)	0.5-24.537	P > 0.05
HCV viremia (IU/mL)	1195000 (362000-3830000)	112000-9850000	3780000 (799000-4290000)	382000-7210000	P > 0.05
ALT (U/L)	54 (43-83)	23-339	45 (44-47)	41-48	P > 0.05
HOMA	(1.02-3.99)	0.78-5.66	2.44 (1.5-2.84)	0.88-9.67	P > 0.05
Adiponectin (μg/mL)	7.56 (6-8.37)	5.33-9.07	6.35 (5.34-8.89)	3.51-18.48	P > 0.05
Osteopontin (ng/mL)	24.33 (22.18-32.98)	13.14-34.58	29.94 (16.79-37.78)	5.33-59.15	P > 0.05
Visfatin (ng/mL)	2.64 (1.57-6.35)	0.65-9.33	2.56 (1.13-5.69)	0.45-9.37	P > 0.05
Leptin (ng/mL)	13.11 (8.56-17.2)	5.47-39.04	3.04 (1.69-11.94)	0.77-54.65	P > 0.05
Omentin (ng/mL)	367.16 (257.55-399.91)	152.74-522.77	390.95 (341.39-536.18)	115.7-757.34	P > 0.05
Resistin (ng/mL)	1.17 (0.91-1.65)	0.76-1.74	1.55 (1.205-1.83)	0.73-2.92	P > 0.05

The single nucleotide polymorphisms (SNPs) of IL28B (rs 12979860) were not associated with adipokine levels or HOMA-IR index. Genotypes of IL28B: CC and not CC (CT and TT); SOCS-3: Suppressor of cytokine signaling 3; HOMA-IR: Homeostasis model assessment of insulin resistance; ALT: Alanine aminotransferase; LQ: Lower quartile; UQ: Upper quartile.

Citation: Wójcik K, Jabłonowska E, Omulecka A, Piekarska A. Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. World J Gastroenterol 2014; 20(30): 10449-10456
URL: https://www.wjgnet.com/1007-9327/full/v20/i30/10449.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i30.10449